

# Yujiro Naito

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9886938/publications.pdf>

Version: 2024-02-01

12  
papers

227  
citations

1684188

5  
h-index

1281871

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report. <i>Angiogenesis</i> , 2022, 25, 147-149.	7.2	2
2	Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma. <i>Medicine (United States)</i> , 2022, 101, e28476.	1.0	2
3	A case of synchronous triple autoimmune disorders secondary to thymoma: Pure red cell aplasia, Good's syndrome, and thymoma-associated multi-organ autoimmunity. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101619.	0.4	3
4	Identification of CD14 and lipopolysaccharide-binding protein as novel biomarkers for sarcoidosis using proteomics of serum extracellular vesicles. <i>International Immunology</i> , 2022, 34, 327-340.	4.0	5
5	Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer. <i>JCI Insight</i> , 2022, 7, .	5.0	10
6	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. <i>Cancer Research</i> , 2021, 81, 1813-1826.	0.9	41
7	Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. <i>Investigational New Drugs</i> , 2021, 39, 1106-1112.	2.6	8
8	IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor Immunity. <i>Journal of Immunology</i> , 2021, 207, 1456-1467.	0.8	7
9	Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 162, 175-184.	2.0	6
10	Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice. <i>Journal of Controlled Release</i> , 2019, 313, 106-119.	9.9	35
11	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
12	Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e7884.	1.0	16